
The Bose Active Suspension Lives! (On a Chinese Luxury Sedan)
0:00 / 0:00
Electrohydraulic, Not Electromagnetic
Turns out scaling a doorbell plunger or speaker-coil driver up for car suspension duty just couldn't pencil out, but ClearMotion applies much of Bose's control logic to its suspension, which packages a proprietary gerotor hydraulic pump and reservoir at each corner. These units can adjust a wheel's position up or down 60 times faster than an air spring can. To do this, the pump motor makes 1,000 torque adjustments per second in response to actuators with a response time of 40 adjustments per second while moving the wheel through a total range of motion of 108mm. Note that while Bose proposed steel torsion bar springs to bear the vehicle's load while its rams handled damping and leveling, the ET9 uses air springs for these purposes. (This is a major difference between the ClearMotion1 system and the purely hydraulic active corners we covered by Domin.)
Reactive Now, Fully Active Soon?
Bose and ClearMotion both propose reactive suspensions fitted with ultrafast responding sensors, but everyone knows that a suspension that knows the precise size and placement of a bump can better prepare to actively cushion it. All the recent higher-end Nio vehicles are cloud connected, and every one of them has been using their onboard sensor suite to map the road for bumps and potholes, but to date that data isn't quite accurate enough to inform SkyRide. But these new suspension corners are far more accurate at road sensing, so as the fleet of ET9s increases, the high-def map of road irregularities will improve. The companies are also working to train the ADAS sensor suite to better measure and report road irregularities, both to their own onboard suspension corners and to the cloud. All of this promises to make an ET9 purchased today potentially ride better tomorrow.
Edge Use Cases
Along with the ability to kneel for easier entry/egress/cargo loading, or to in an instant to better align the car's skateboard structure with another vehicle's bumper prior to an impending impact, the ET9 has some other party tricks. Its suspenders can be made to dance on command. There's a suspension demo mode, in which the front center screen plays videos of different road surfaces, depicting the ride quality a 'normal' car might provide, then plays them back in SkyRide mode for contrast. Then there's also the world's production example of 5D PanoCinema mode, in which the car can be made to shake and vibrate in conjunction with action in a movie playing on the screen(s). But perhaps our favorite is 'Soccer Maze,' a gaming demo in which the car can be connected to a Nio Phone 2 (yes Nio makes phones now, too) via Bluetooth, allowing the phone's gyroscope to control pitch and roll while a tabletop football game on the roof moves the ball around.
How Much Power Does SkyRide Draw?
Nio engineers were pretty cagey on this topic, but translating one of the graphics in a SkyRide presentation noted a power figure 10kW. That has to be a max draw rate during 5D PanoCinema use with a lot of up and down motion, because there's no reason these units should draw significantly more power than the Domin ones, which were quoted at 1kW during a ride height increase adjustment. There should be no significant power draw while riding down a smooth road.
How Does It Ride?
Remembering that we're still sampling the system before it's totally cloud-informed, it rides very smoothly, but not cloud-like. You still sense all the bumps as the system reacts and greatly lessens their effect. It is exceptionally good at bridge ramps (these it can prepare for). The suspension rises a little in advance, absorbs the uphill ramp, levels off, and descends the other side with exception grace. And experiencing the demo, which showed a road very like one we'd driven on near the Nio headquarters with rubber speed bumps applied, the difference before and after engaging SkyRide was stark, and the after felt representative of our experience on that road. We also watched folks watching a movie with cars bucking like broncos on an extremely rough course, and the car impressed by matching the action faithfully.
When Might We Get ClearMotion1?
Porsche signed a licensing deal with ClearMotion in April 2024 and we're told others will be announcing similar deals soon. Nio also has technology sharing agreements with McLaren. So expect this tech to make it's North American debut on something expensive.
But Will It…Fly?
We seriously doubt these gerotor pumps have the speed, power, and fluid capacity needed to launch 2.5 tons of luxury sedan skyward. But we'd definitely click on a video of it doing so.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
1 Unstoppable Growth Stock That's On Track to Double by 2030
Key Points A weak auto market is likely to benefit auto parts retailers like O'Reilly Automotive. Anemic job growth may cause consumers to delay new car purchases, which also helps O'Reilly. O'Reilly's valuation is currently high, which might concern some investors. 10 stocks we like better than O'Reilly Automotive › Five years ago, who would've guessed that O'Reilly Automotive (NASDAQ: ORLY) would be one of the market's big winners? But its share price is up roughly 240% since then on a split-adjusted basis, crushing the S&P 500's five-year return of 106%. How did O'Reilly do it? Well, besides having one of the catchiest jingles out there ("Oh, Oh, Oh, O'Reillyyyyyyyy...!"), the company has been rapidly opening new stores and buying back stock. Its shares just split 15-for-1 in June. Even though its split-adjusted share price has doubled in less than three years, O'Reilly stock could double again by 2030. Here's how. Weak auto sales are an auto parts retailer's dream U.S. auto sales have been going through a rough patch, and recent trade policy changes seem likely to make things worse in the short term. New tariffs on auto imports and various imported auto components have now kicked in on top of already high tariffs on automaking essentials like aluminum. This seems almost certain to boost the price of a new car by thousands of dollars. That will likely drive up used car prices as well, pushing down already weak demand even further. That may be bad for U.S. automakers, but it's a boon for an auto parts supplier like O'Reilly. A slump in vehicle purchasing means that people hang onto their existing cars for longer. And the longer you have a car, the more likely it is that something on it -- whether it's a headlight bulb or an automatic transmission -- will need to be replaced, and O'Reilly will be happy to sell it to you (or to your mechanic). Weak job numbers are an auto parts retailer's dream Meanwhile, recent Labor Department data indicates that the U.S. job market may be softening. In its latest report, the U.S. Bureau of Labor Statistics (BLS) reported that just 73,000 jobs were created in July, far fewer than many economists anticipated. The BLS also revised the previous two months' job numbers down significantly. That matches recent anecdotal evidence that hiring has substantially slowed. When people are unable to find a job -- or worried about hanging onto the one they have -- they're unlikely to make a major purchase like a new car, or even a used car. If hiring slows further or if the U.S. tips into a full-blown recession, many drivers may have no choice but to hang onto their existing vehicle, even if it's got problems. That may be bad for carmakers, but it's good for O'Reilly, which sells the parts needed to keep a clunker on the road. A high valuation is a stock buyer's nightmare One big concern for potential O'Reilly investors is how much its share price has risen. The company's trailing price-to-sales (P/S) ratio of 5.2 is already much higher than that of rivals Autozone (NYSE: AZO) or Advance Auto Parts (NYSE: AAP), which sit at 3.6 and 0.4, respectively. Its price-to-earnings (P/E) ratio has jumped to a multidecade high of 36.4, also well above that of its rivals. That said, given the company's solid track record and excellent prospects for further growth, its premium valuation makes sense. For O'Reilly's share price to double by 2030, it would need to increase by a compound annual growth rate (CAGR) of about 15% per year. That seems achievable. In the most recent quarter, diluted earnings per share were up 11% year over year, and management projected a 3% net increase in store count for the year. Add a few additional percentage points of sales growth from weakening auto sales and a softening labor market, and you could easily get a 15% CAGR for O'Reilly stock. Of course, nothing is guaranteed, but even if O'Reilly falls short of a five-year double, it should still end up a long-term winner for investors. Do the experts think O'Reilly Automotive is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did O'Reilly Automotive make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,071% vs. just 185% for the S&P — that is beating the market by 886.18%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $663,630!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,115,695!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 John Bromels has positions in O'Reilly Automotive. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. 1 Unstoppable Growth Stock That's On Track to Double by 2030 was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Bernstein Reiterates Outperform on TSMC (TSM), Citing Strategic Chip Role
Taiwan Semiconductor Manufacturing Company Ltd (NYSE:TSM) is one of the best growth stocks to buy according to analysts. On August 15, Bernstein reiterated its Outperform rating on Taiwan Semiconductor Manufacturing Company Ltd (NYSE:TSM), with a price target of $249.00. That represents an implied upside of only 4.1% from the current price of $239.1. A close-up of a complex network of integrated circuits used in logic semiconductors. However, Bernstein cited the Taiwanese company's strategic importance in the global semiconductor landscape, emphasizing that it accounts for roughly 15–25% of the worldwide wafer fab equipment (WFE) market. That is massive, especially considering the whole of China's share of 30–40%. Bernstein also cited that a significant share of the company's capital expenditures is allocated beyond just traditional wafer fabrication. According to the firm, TSMC is increasingly investing higher amounts in infrastructure, packaging, and testing technologies. These are critical components in advanced chip production. Last month, the company delivered a stellar Q2 2025 performance, with revenue climbed to NT$933.79 billion (US $30.07 billion), up 38.6 % year-over-year; while net income reached NT$398.27 billion (about US $13.53 billion), and diluted EPS came in at NT$15.36 (US $2.47 per ADR), a whopping 60.7 % jump year-over-year. While we acknowledge the potential of TSM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


New York Times
2 hours ago
- New York Times
China's Biotech Is Cheaper and Faster
Just outside of Shanghai, in the city of Wuxi, China is building its future of medicine — a booming biotechnology hub of factories and laboratories where global pharmaceutical companies can develop and manufacture drugs faster and cheaper than anywhere else. Amid the Trump administration's tariffs on China, I figured manufacturing hubs like this one would be wracked with anxiety. But when I visited Wuxi in April, government officials insisted that its research hub was flourishing. They were proud to tell me about their superstar labs and companies that are continuing to thrive. The fact that Chinese biotechnology stocks have surged over 60 percent since January seems to bolster this claim. The city's researchers certainly seemed positioned to be busy for decades. In its quest to dethrone American dominance in biotech, China isn't necessarily trying to beat America at its own game. While the U.S. biotech industry is known for incubating cutting-edge treatments and cures, China's approach to innovation is mostly focused on speeding up manufacturing and slashing costs. The idea isn't to advance, say, breakthroughs in the gene-editing technology CRISPR; it's to make the country's research, development, testing and production of drugs and medical products hyperefficient and cheaper. As a result, China's biotech sector can deliver drugs and other medical products to customers at much cheaper prices, including inexpensive generics. These may not be world-changing cures, but they are treatments that millions of people around the world rely on every day. And as China's reach expands, the world will soon have to reckon with a new leader in biotech and decide how it wants to respond. One such company that embodies the Chinese approach to biotech is Wuxi AppTec. It's a one-stop shop for pharmaceutical research and development, streamlining everything from early-stage drug discovery to young scientist recruitment and medication production. The company, whose clients have included Chinese firms like Innovent and Jiangsu Hengrui, as well as American and European drugmakers like Pfizer, GlaxoSmithKline and AstraZeneca, was involved in, by one estimate, a quarter of the drugs used in the United States, including blockbuster cancer drugs. Though the Chinese government bargains hard with both foreign and domestic pharmaceutical companies to provide products at the right price in exchange for market access, the low prices that Chinese consumers pay are ultimately the result of Chinese biotech companies' ability to test and manufacture drugs at a pace far faster than their American counterparts. So far, American biotech giants don't seem to mind the competition, since their own use of companies like Wuxi AppTec allows them to dedicate more of their money to breakthrough research. Want all of The Times? Subscribe.